Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688347 · ClinicalTrials.gov registry record
Microbiome in Lung Cancer and Other Malignancies
A clinical trial of Cancer and Lung Cancer, sponsored by Taher Abu Hejleh.
- Completed
- Registry status
- 44
- Enrollment target
- 1
- Study location
NCT03688347: Completed study of Cancer and Lung Cancer, sponsored by Taher Abu Hejleh.
NCT03688347 is a study of Cancer and Lung Cancer that has completed, run by Taher Abu Hejleh. The registered enrollment target is 44 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03688347, a study of Cancer and Lung Cancer, has completed, sponsored by Taher Abu Hejleh.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.
Primary Outcome
Bacterial DNA will be isolated from stool/swab samples using standard protocol. Fecal micobiota will be examined based on an 16S rRNA amplicon.
Conditions Studied
Interventions
- PROCEDURE Nasal Swab
- OTHER Stool Collection
- PROCEDURE Oral Swab
- GENETIC Microbiome analysis
- GENETIC DNA Banking
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2022-05-09 |
What the finished NCT03688347 record still lists
NCT03688347 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nasal Swab is the first listed.
NCT03688347 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT03688347 about?
NCT03688347 is a clinical study titled "Microbiome in Lung Cancer and Other Malignancies". To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.
What is the current status of trial NCT03688347?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2018-08-30. Estimated completion is 2022-05-09.
What conditions does trial NCT03688347 study?
This clinical trial studies the following conditions: Cancer, Lung Cancer, Malignancy.
What interventions are being tested in trial NCT03688347?
The interventions under investigation include: Nasal Swab (PROCEDURE), Stool Collection (OTHER), Oral Swab (PROCEDURE), Microbiome analysis (GENETIC), DNA Banking (GENETIC).
Who is sponsoring clinical trial NCT03688347?
This trial is sponsored by Taher Abu Hejleh, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03688347 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03688347's enrollment target sits among peer trials
44 449th of 615 higher than 162 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI